Informations générales (source: ClinicalTrials.gov)
Regulatory B Cells in Inflammatory Rheumatisms, Systemic Auto-immune Diseases in Adults and Biomarkers of Response to Biologic Treatments
Observational
University Hospital, Montpellier (Voir sur ClinicalTrials)
juillet 2012
décembre 2020
29 juin 2024
B cells are known to play an important role in auto-immune diseases by activating T
cells, secreting inflammatory cytokines and autoreactive antibodies. However, a sub-type
of B cells named regulatory B cells or Bregs has recently shown capacities to prevent or
cure arthritis in mouse models. Bregs have also been identified in humans.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Lapeyronie Hospital - 34295 - Montpellier - France | Jacques Morel, MD, PhD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
For RA patients and control patients:
- Age over 18 year old
- Blood sample taken as part of the usual management
- Steroid less than or equal to 15 mg/day and stable for at least a week
For RA patients:
- Patient with RA meeting the ACR / EULAR 2010
For control patients:
- Patients with systemic autoimmune disease (lupus, Sjogren's syndrome, scleroderma)
or other inflammatory arthritis (spondylitis, crystals) or a mechanical pathology
(limb osteoarthritis or spinal pathology) .
For RA patients and control patients:
- Age over 18 year old
- Blood sample taken as part of the usual management
- Steroid less than or equal to 15 mg/day and stable for at least a week
For RA patients:
- Patient with RA meeting the ACR / EULAR 2010
For control patients:
- Patients with systemic autoimmune disease (lupus, Sjogren's syndrome, scleroderma)
or other inflammatory arthritis (spondylitis, crystals) or a mechanical pathology
(limb osteoarthritis or spinal pathology) .
- steroids over 15 mg/day
- rituximab infusion in less than 12 months